share_log

6-K: Tolebrutinib Meets Primary Endpoint in HERCULES Phase 3 Study, The First and Only to Show Reduction in Disability Accumulation in Non-relapsing Secondary Progressive Multiple Sclerosis

6-K: Tolebrutinib Meets Primary Endpoint in HERCULES Phase 3 Study, The First and Only to Show Reduction in Disability Accumulation in Non-relapsing Secondary Progressive Multiple Sclerosis

6-K:托勒布替尼在HERCULES 3期研究中達到主要終點,這是第一個也是唯一一個顯示非復發繼發性進行性多發性硬化癥殘疾積累減少的研究
美股SEC公告 ·  2024/09/03 22:51
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息